Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer.

Translational research : the journal of laboratory and clinical medicine - 1 Jun 2018

Zhao Xianda, May Audre, Lou Emil, Subramanian Subbaya

Abstract excerpt

Immune checkpoint blockade therapy (ICBT) has resulted in extended overall survival for some patients with certain types of cancer, most prominently including colorectal cancer (CRC) associated with microsatellite instability (MSI). However, most patients with CRC whose phenotypes have microsatellite stability (MSS) are unresponsive to ICBT. In efforts to understand the responsiveness of CRC tumors to ICBT,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CTLA-4 Antigen

Share to DNA Damage

Share to Genotype

Share to Microsatellite Instability

Share to Neoplastic Syndromes, Hereditary

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 29518351
DOI: 10.1016/j.trsl.2018.02.001
PMCID: PMC5949270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer.PMID 29518351Read ↗

Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives.Semantic proximity Read ↗

Predictors of response to immunotherapy in colorectal cancerSemantic proximity Read ↗

Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving SagaSemantic proximity Read ↗

Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal CancerSemantic proximity Read ↗

Advances in immunotyping of colorectal cancerSemantic proximity Read ↗

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair DeficiencySemantic proximity Read ↗

The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancerSemantic proximity Read ↗

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer LandscapeSemantic proximity Read ↗

The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.Semantic proximity Read ↗

Tumor mutational burden predicts neoantigen profiles and immunotherapy response in microsatellite stable tumors across different cancer types.Semantic proximity Read ↗

Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatmentSemantic proximity Read ↗

Predictive biomarkers for immune checkpoint inhibition for patients with colorectal cancer: a comprehensive review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.